Investors
Our investor proposition
GSK is a science-led global healthcare company that aims to deliver growth and improving returns to shareholders through the development of innovative pharmaceutical, vaccine and consumer healthcare products.
Key information
2019 second quarter results announcement
We will announce our second quarter 2019 results at 12:00 BST, 07:00 EDT on Wednesday 24 July.
Following the announcement there will be a webcast, hosted by Emma Walmsley, CEO; Iain Mackay, CFO; and Hal Barron, Chief Scientific Officer and President, R&D at 14:00 BST, 09:00 EDT.
Latest information
Press releases
- IAS 2019: ViiV Healthcare showcasing innovation in HIV science
- GSK announces positive headline results in Phase 3 PRIMA study of ZEJULA (niraparib) for patients with ovarian cancer in the first line maintenance setting
- ViiV Healthcare announces phase III study meets primary endpoint, demonstrating the ability to control HIV-1 with a 2-drug regimen of dolutegravir plus lamivudine in virally suppressed patients switching from a TAF-containing, 3-drug regimen
Annual Report 2018
We published our Annual Report 2018 on 12 March 2019. View the summary and download the full report or individual sections.